Full-Time

Senior Associate Software Engineer

Gen AI

Updated on 8/23/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's

Category
AI & Machine Learning (1)
Software Engineering (1)
Required Skills
LLM
Python
React.js
Software Testing
Git
UiPath
SQL
OpenAI
GraphQL
Docker
RAG
TypeScript
Tableau
Role-based Access Control
AWS
JIRA
n8n
LangGraph
Next.js
REST APIs
LangChain
DevOps
Databricks
Serverless
OAuth

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Any degree and 5 to 9 years of relevant experience in Computer Science, Information Technology, Engineering, Data Science, or a related field.
  • At least 4 years of professional experience in software development, application engineering, systems integration, or system design.
  • At least 2 years of hands-on experience building, deploying, or supporting production generative artificial intelligence applications, assistants, agents, Custom GPTs, retrieval-augmented generation solutions, or comparable AI-enabled software.
  • Strong hands-on proficiency in Python and experience developing, testing, debugging, and maintaining production applications, APIs, data services, or integration components.
  • Hands-on experience with prompt and context design, embeddings, vector databases or search, retrieval pipelines, structured outputs, tool integration, agent orchestration, evaluation, guardrails, and observability.
  • Experience designing and building cloud-native solutions, preferably on Amazon Web Services, using services such as Amazon Bedrock, AWS Lambda, Amazon EKS or ECS, API Gateway, IAM, networking, monitoring, and event-driven integration.
  • Experience designing secure RESTful or GraphQL integrations using API gateways, OAuth, service identities, enterprise authentication, role-based access, secrets management, and least-privilege principles.
  • Experience with automated testing, source control, code review, Git-based workflows, continuous integration and continuous delivery, and responsible use of AI-assisted software development tools.
  • Experience building modern web applications using TypeScript, React, Next.js, component-driven architecture, state management, design systems, and API integration.
  • Working knowledge of SQL, files, databases, and governed data-access patterns, with troubleshooting and analytical skills across application, model, data, integration, and infrastructure layers.
  • Strong verbal and written communication skills and the ability to produce clear technical documentation.
  • Ability to collaborate with global, distributed, cross-functional teams using agile or scaled agile ways of working.
  • Ability to manage multiple priorities, assess gaps and fit, communicate technical risks and tradeoffs, and support shared team outcomes.
Responsibilities
  • Design, develop, test, and deploy LLM-powered assistants, agents, Custom GPTs, retrieval-augmented generation solutions, APIs, and AI-enabled applications on ChatGPT Enterprise and other approved platforms.
  • Implement prompt and context strategies, structured outputs, embeddings, vector or hybrid retrieval, tool calling, workflow orchestration, and human-in-the-loop controls.
  • Build scalable retrieval-augmented generation pipelines that ground responses in trusted enterprise data.
  • Contribute to the generative artificial intelligence capability roadmap through implementation of MCP-based Apps, ChatGPT Skills, plugins, Workspace Agents, and reusable integration patterns.
  • Develop integration layers and event-driven workflows using APIs, robotic process automation, n8n, and approved orchestration tools to connect systems and trigger agent workflows.
  • Develop reusable Python services, libraries, templates, and evaluation utilities, and contribute TypeScript, React, or Next.js components when required by the solution.
  • Implement automated unit, integration evaluation, and end-to-end tests, along with tracing and monitoring for retrieval quality, response consistency, and reliability.
  • Implement safeguards for prompt injection, data leakage, unauthorized retrieval, insecure tool execution, secrets exposure, excessive agency, and inappropriate model outputs.
  • Apply secure integration and identity patterns using API gateways, OAuth, service identities, delegated authorization, role-based access control, secrets management, least privilege, and user-level auditability.
  • Build and maintain continuous integration and continuous delivery pipelines and approved cloud deployment configurations using AWS services, containers, serverless compute, or managed platform capabilities.
  • Troubleshoot defects across application, model, retrieval, data, integration, and infrastructure layers; support incident investigation, remediation, rollback, patching, and performance tuning.
  • Create and maintain technical designs, test evidence, runbooks, deployment instructions, and handover materials that support sustainable operations.
  • Partner with functional teams, product owners, architects, business subject matter experts, data engineers, platform teams, DevOps, cybersecurity, privacy, and responsible artificial intelligence stakeholders to translate requirements into reliable solutions.
  • Participate in agile planning, backlog refinement, estimation, demonstrations, retrospectives, release activities, and technical design reviews.
  • Review code and technical designs, apply software engineering standards, and use AI-assisted development tools such as OpenAI Codex or GitHub Copilot with appropriate review, security, and quality controls.
  • Support office hours, technical enablement sessions, junior engineers, and knowledge-sharing through reusable examples, engineering patterns, and lessons learned.
  • Communicate delivery status, technical risks, dependencies, defects, and recommendations clearly to technical and non-technical stakeholders.
Desired Qualifications
  • Experience with OpenAI APIs and software development kits, MCP servers and Apps, ChatGPT Skills, plugins, Workspace Agents, LangChain, LangGraph, n8n, or comparable agent technologies.
  • Experience with Amazon Bedrock and related agent capabilities, AWS Lambda, Amazon EKS or ECS, Amazon EC2, API Gateway, IAM, VPC networking, or event-driven services.
  • Experience with Databricks, Unity Catalog, Vector Search, SQL Warehouses, semantic layers, or governed natural-language-to-SQL solutions.
  • Experience with Power Automate, UiPath, Tableau, Jira, Smartsheet, or comparable automation and delivery tools.
  • Experience with model and application evaluation, red teaming, responsible AI, AI security, GxP, computer-system validation, regulated technology environments, or relevant technical certifications.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.